Here we report purification and crystallization of the isolated toxin VapC (MvpT) from the VapBC toxin-antitoxin complex of the pathogen Shigella flexneri. The crystals belong to space group H3 and diffract to 1.9 Å resolution.
Introduction
Toxin-antitoxin (TA) loci have been found in all prokaryotic genomes that have been sequenced to date and typically encode two proteins, a toxin and an antitoxin that associate to form a tight complex in which binding of the antitoxin inhibits the cellular action of the toxin (Makarova et al., 2009; Pandey & Gerdes, 2005) . Upon changes in the cellular environment, such as during oxidative stress or nutrient deprivation, the antitoxin undergoes degradation and the more stable toxin is freed from the inhibitory TA complex. Once released, many toxins are active as nucleases that are able to cleave specific cellular RNAs and thus induce growth arrest by down-regulating the overall translational rate (Ahidjo et al., 2011; Yamaguchi & Inouye, 2009 ). The antitoxins, on the other hand, contain a DNAbinding domain conferring high affinity for the TA promoter, enabling auto-regulation of the level of transcription from the TA operon . TA gene pairs can be subdivided into several families, of which the vapBC (virulence associated proteins) loci are the most abundant (Pandey & Gerdes, 2005) . Interestingly, vapBC loci are particularly common in pathogenic bacteria (Ramage et al., 2009) where they are involved in bacterial persister cell formation and thus highly relevant in disease control (Maisonneuve et al., 2011) .
VapC toxins are characterized by an approximately 100 amino acid N-terminal ribonuclease motif belonging to the PilT N-terminus (PIN) domain type. This domain harbours four highly conserved acidic residues that have been shown to be essential for metal ion coordination in other PIN domaincontaining ribonucleases, but the exact enzymatic mechanism used by the VapC toxins is yet unresolved (Backbro et al., 2004; Fatica et al., 2004) . The VapB antitoxins are highly specific towards their cognate toxins and inhibit the ribonucleolytic activity through direct interaction (Ramage et al., 2009) . Crystal structures have been determined of both VapBC-like complexes and isolated VapC-like toxins from archaea and pathogenic bacteria, which show a great diversity in both sequence, structure, as well as the cellular target of the toxin (Bunker et al., 2008; Mattison et al., 2006; Miallau et al., 2009) . Like for most other TA systems, VapBC complexes bind to the operator sequences of their own promoter region and down-regulate transcription from the operon (Bodogai et al., 2006; Wilbur et al., 2005) . A recent crystal structure of the intact VapBC complex from the Gram-negative pathogen, Shigella flexneri, revealed the DNA-binding complex is a compact heterooctameric assembly with the two DNA-binding domains juxtaposed in a manner compatible with adjacent major groove binding (Dienemann et al., 2011) . This structure also showed that VapB inhibits VapC through displacement of divalent metal ions at the active site.
Once activated, S. flexneri VapC (MvpT) has been found to specifically target the anticodon region of tRNA fMet through endoribonucleolytic cleavage by a mechanism involving Asp7 of VapC . In order to understand the basis of target RNA recognition and the enzymatic mechanism employed by the Shigella VapC toxin in degrading tRNA fMet , we introduced the D7A mutation with the aim of determining the structure of the VapC D7A in isolation as well as bound to the anticodon region of tRNA fMet . Here we report the expression, purification and crystallization of the isolated VapC D7A (MvpT) toxin as well as initial crystallographic analysis of diffraction data collected to 1.9 Å. The results provide a basis for determining the crystal structure of the isolated toxin and thus understanding both the principle of toxin activation as well as the mechanism of the ribonucleolytic activity of VapC.
Materials and methods

Cloning
The vapC D7A gene with codon seven encoding aspartate substituted with an alanine codon was amplified from plasmid pKW254813 
Expression and purification
pKW2583HN was transformed into Escherichia coli C41 (DE3) for expression . The cells were grown in LB medium at 37 °C containing 100 mg/mL ampicillin until OD 600 reached 0.5 and were subsequently induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) overnight at 25 °C with shaking at 120 rpm. Cells were harvested by centrifugation at 12,000 g for 15 min and resuspended in lysis buffer containing 50 mM Tris, pH 8.0, 500 mM KCl, 5 mM MgCl 2 , 5 mM 2-mercaptoethanol, 10 mM imidazole, and protease inhibitor tablets (Sigma). Cells were opened by a combination of sonication and high-pressure homogenization at 15,000 psi and the lysate cleared by centrifugation at 15,000 rpm for 45 min. The resulting supernatant was loaded onto a pre-packed 5 mL HiTrap column (GE Healthcare) charged with Ni 2+ followed by extensive washing of the column (20 CV) in a buffer identical to the lysis buffer but including 35 mM imidazole. Elution was finally achieved with a very similar buffer only containing 250 mM imidazole. Next, the protein pool was concentrated to 3.37 mg/mL by ammonium sulphate precipitation (65% saturation) and resuspended in 25 mM Mes, pH 6.0, 5 mM MgCl 2 , and 5 mM 2-mercaptoethanol. As a final step, a monodisperse protein sample was obtained using a Superdex 75 10/300 HR size exclusion column (GE Healthcare) running in 25 mM Mes, pH 6.0, 50 mM KCl, 5 mM MgCl 2 , and 5 mM 2-mercaptoethanol.
Crystallization
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Prior to crystallization, the monodisperse sample of VapC D7A was concentrated to 4 mg/mL using a 
X-ray data collection and processing
Single crystals were transferred into a solution containing initially 25% w/v followed by 30% w/v PEG 3350 in 0.05 M citric acid and 0.05 M Bis-Tris propane, pH 5.0 using a mounted CryoLoops (Hampton Research), and then flash frozen in liquid nitrogen. All data were collected at 100 K on beamline I911-2 (wavelength 1.04 Å) at MAX-Lab (Lund, Sweden) and processed with XDS (Kabsch, 2010) through Xia2 (Winter, 2010) . Matthews' parameters were calculated using matthews_coef as implemented in CCP4 (Matthews, 1968; Winn et al., 2011) .
Results and discussion
The D7A active site mutant of VapC, which has been shown to be inactive in vivo, can readily be expressed in E. coli and purified directly in the absence of the antitoxin VapB . Essentially pure VapC D7A was obtained by Ni-NTA chromatography followed by size exclusion chromatography (Figure 1 ). The protein elutes after 13.5 mL from a standard 24 mL The flash-frozen VapC D7A crystals diffract to beyond 1.9 Å at a synchrotron x-ray source and a full data set was collected at MAX-Lab, Lund and processed by XDS (Kabsch, 2010) through Xia2 (Winter, 2010) . A summary of the data and processing statistics are shown in Table 1 . The crystals belong to the trigonal space group in hexagonal setting, H3 (space group number 146), with unit cell parameters a=b=120.1Å, c=52.5 Å, α=β=90°, γ=120°. The Matthews' coefficient and solvent content were estimated using CCP4 (Winn et al., 2011) In summary, the purification, crystallization, and preliminary crystallographic analysis of the S.
flexneri VapC D7A toxin reported here form the basis for determining the structure of the active conformation of the isolated toxin upon release of the anti-toxin, VapB. This structure will allow us to better understand the mechanism of toxin activation for the VapBC toxin-antitoxin family as well as the catalytic mechanism of the toxin. On the longer term, co-crystallization with tRNA fMet will allow a full understanding of the toxin target specificity and the cleavage mechanism. 
